Addition of Nitazoxanide to PEG-IFN and Ribavirin to Improve HCV Treatment Response in HIV-1 and HCV Genotype 1 Coinfected Persons Naïve to HCV Therapy: Results of the ACTG A5269 Trial

BACKGROUND: We hypothesized that nitazoxanide (NTZ) added to pegylated inter-feron alfa-2a (PEG-IFN) and weight-based ribavirin (WBR) would improve hepatitis C virus (HCV) virologic responses in HCV treatment-naïve HIV-1/HCV genotype 1 coin-fected persons. METHODS: Prospective, single-arm study in w...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Amorosa, Valerianna K., Luetkemeyer, Anne, Kang, Minhee, Johnson, Victoria A., Umbleja, Triin, Haas, David W., Yesmin, Suria, Bardin, Matthew C., Chung, Ray T., Alston-Smith, Beverly, Tebas, Pablo, Peters, Marion G.
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4113390/
https://ncbi.nlm.nih.gov/pubmed/24334180
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1310/hct1406-274
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items